Basit öğe kaydını göster

dc.contributor.authorKaymakoglu, Sabahattin
dc.contributor.authorUstek, Duran
dc.contributor.authorOnel, Derya
dc.contributor.authorYenen, Osman Sadi
dc.contributor.authorBadur, Selim
dc.contributor.authorAbaci, Neslihan
dc.contributor.authorKursun, Olcay
dc.contributor.authorGumus, Ergun
dc.contributor.authorMese, SEVİM
dc.contributor.authorBozkaya, Emel
dc.contributor.authorArikan, Muzaffer
dc.contributor.authorCakiris, Aris
dc.date.accessioned2021-03-06T11:54:53Z
dc.date.available2021-03-06T11:54:53Z
dc.identifier.citationMese S., Arikan M., Cakiris A., Abaci N., Gumus E., Kursun O., Onel D., Ustek D., Kaymakoglu S., Badur S., et al., "Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients", JOURNAL OF GENERAL VIROLOGY, cilt.94, ss.2729-2738, 2013
dc.identifier.issn0022-1317
dc.identifier.othervv_1032021
dc.identifier.otherav_f15e6f34-aef7-4226-a107-24525bd6b2b7
dc.identifier.urihttp://hdl.handle.net/20.500.12627/158342
dc.identifier.urihttps://doi.org/10.1099/vir.0.053041-0
dc.description.abstractDespite the effectiveness of nucleoside/nucleotide analogues in the treatment of chronic hepatitis B (CHB), their long-term administration is associated with the emergence of resistant hepatitis B virus (HBV) mutants. In this study, mutations resulting in antiviral resistance in HBV DNA samples isolated from 23 CHB patients (nine treatment naive and 14 treated previously) were studied using a line probe assay (INNO-LiPA HBV DR; Innogenetics) and ultradeep pyrosequencing (UDPS) methods. Whilst the INNO-LiPA HBV DR showed no resistance mutations in HBV DNA samples from treatment-naive patients, mutations mediating lamivudine resistance were detected in three samples by UDPS. Among patients who were treated previously, 19 mutations were detected in eight samples using the INNO-LiPA HBV DR and 29 mutations were detected in 12 samples using UDPS. All mutations detected by the INNO-LiPA HBV DR were also detected by UDPS. There were no mutations that could be detected by INNO-LiPA HBV DR but not by UDPS. A total of ten mutations were detected by UDPS but not by INNO-LiPA HBV DR, and the mean frequency of these mutations was 14.7%. It was concluded that, although INNO-LiPA HBV DR is a sensitive and practical method commonly used for the detection of resistance mutations in HBV infection, UDPS may significantly increase the detection rate of genotypic resistance in HBV at an early stage.
dc.language.isoeng
dc.subjectYaşam Bilimleri
dc.subjectBİYOTEKNOLOJİ VE UYGULAMALI MİKROBİYOLOJİ
dc.subjectMikrobiyoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectVİROLOJİ
dc.subjectİmmünoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMikrobiyoloji ve Klinik Mikrobiyoloji
dc.subjectViroloji
dc.subjectBiyoteknoloji
dc.subjectTemel Bilimler
dc.titleRole of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients
dc.typeMakale
dc.relation.journalJOURNAL OF GENERAL VIROLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume94
dc.identifier.startpage2729
dc.identifier.endpage2738
dc.contributor.firstauthorID190


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster